Literature DB >> 25488748

miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Myriem Boufraqech1, Naris Nilubol1, Lisa Zhang1, Sudheer Kumar Gara1, Samira M Sadowski1, Amit Mehta2, Mei He1, Sean Davis3, Jennifer Dreiling4, John A Copland5, Robert C Smallridge6, Martha M Quezado4, Electron Kebebew7.   

Abstract

Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial-mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25488748      PMCID: PMC6986377          DOI: 10.1158/0008-5472.CAN-14-2304

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Altered adhesion features and signal transduction in NRK-49F cells transformed by down-regulation of lysyl oxidase.

Authors:  Monia Giampuzzi; Roberta Oleggini; Armando Di Donato
Journal:  Biochim Biophys Acta       Date:  2003-04-11

2.  Anaplastic thyroid carcinoma: a 50-year experience at a single institution.

Authors:  B McIver; I D Hay; D F Giuffrida; C E Dvorak; C S Grant; G B Thompson; J A van Heerden; J R Goellner
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

3.  Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors.

Authors:  Electron Kebebew; Francis S Greenspan; Orlo H Clark; Kenneth A Woeber; Alex McMillan
Journal:  Cancer       Date:  2005-04-01       Impact factor: 6.860

4.  Hydrogen peroxide-mediated, lysyl oxidase-dependent chemotaxis of vascular smooth muscle cells.

Authors:  W Li; G Liu; I N Chou; H M Kagan
Journal:  J Cell Biochem       Date:  2000-06-12       Impact factor: 4.429

5.  Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy.

Authors:  Christelle P El-Haibi; George W Bell; Jiangwen Zhang; Anthony Y Collmann; David Wood; Cally M Scherber; Eva Csizmadia; Odette Mariani; Cuihua Zhu; Antoine Campagne; Mehmet Toner; Sangeeta N Bhatia; Daniel Irimia; Anne Vincent-Salomon; Antoine E Karnoub
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-02       Impact factor: 11.205

6.  MicroRNAs modulate hematopoietic lineage differentiation.

Authors:  Chang-Zheng Chen; Ling Li; Harvey F Lodish; David P Bartel
Journal:  Science       Date:  2003-12-04       Impact factor: 47.728

Review 7.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

8.  Reaction of aortic lysyl oxidase with beta-aminopropionitrile.

Authors:  S S Tang; P C Trackman; H M Kagan
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

9.  NCBI GEO: archive for functional genomics data sets--update.

Authors:  Tanya Barrett; Stephen E Wilhite; Pierre Ledoux; Carlos Evangelista; Irene F Kim; Maxim Tomashevsky; Kimberly A Marshall; Katherine H Phillippy; Patti M Sherman; Michelle Holko; Andrey Yefanov; Hyeseung Lee; Naigong Zhang; Cynthia L Robertson; Nadezhda Serova; Sean Davis; Alexandra Soboleva
Journal:  Nucleic Acids Res       Date:  2012-11-27       Impact factor: 16.971

10.  The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells.

Authors:  Alla Bondareva; Charlene M Downey; Fabio Ayres; Wei Liu; Steven K Boyd; Benedikt Hallgrimsson; Frank R Jirik
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

View more
  31 in total

1.  Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Authors:  Myriem Boufraqech; Dhaval Patel; Naris Nilubol; Astin Powers; Timothy King; Jasmine Shell; Justin Lack; Lisa Zhang; Sudheer Kumar Gara; Viswanath Gunda; Joanna Klubo-Gwiezdzinska; Suresh Kumar; James Fagin; Jeffrey Knauf; Sareh Parangi; David Venzon; Martha Quezado; Electron Kebebew
Journal:  Thyroid       Date:  2018-12-28       Impact factor: 6.568

Review 2.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

3.  The overexpression of miR-30a affects cell proliferation of chondrosarcoma via targeting Runx2.

Authors:  Dong Jiang; Xiaoming Zheng; Wei Shan; Ying Shan
Journal:  Tumour Biol       Date:  2015-11-23

4.  Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.

Authors:  Myriem Boufraqech; Lisa Zhang; Naris Nilubol; Samira M Sadowski; Shweta Kotian; Martha Quezado; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2016-03-30       Impact factor: 12.531

5.  Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss.

Authors:  Lee Ann Jolly; Sergey Novitskiy; Phillip Owens; Nicole Massoll; Nikki Cheng; Wei Fang; Harold L Moses; Aime T Franco
Journal:  Cancer Res       Date:  2016-01-27       Impact factor: 12.701

Review 6.  The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication.

Authors:  Laura MacDonald; Jonathan Jenkins; Grace Purvis; Joshua Lee; Aime T Franco
Journal:  Horm Cancer       Date:  2020-06-17       Impact factor: 3.869

7.  Overexpression of miR-30a in lung adenocarcinoma A549 cell line inhibits migration and invasion via targeting EYA2.

Authors:  Yuncang Yuan; Shangyong Zheng; Qian Li; Xudong Xiang; Tangxin Gao; Pengzhan Ran; Lijuan Sun; Qionglin Huang; Fei Xie; Jing Du; Chunjie Xiao
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-02-01       Impact factor: 3.848

8.  The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition.

Authors:  Urbain Weyemi; Christophe E Redon; Rohini Choudhuri; Towqir Aziz; Daisuke Maeda; Myriem Boufraqech; Palak R Parekh; Taresh K Sethi; Manjula Kasoji; Natalie Abrams; Anand Merchant; Vinodh N Rajapakse; William M Bonner
Journal:  Nat Commun       Date:  2016-02-15       Impact factor: 14.919

9.  miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.

Authors:  Rosanna Sestito; Roberta Cianfrocca; Laura Rosanò; Piera Tocci; Elisa Semprucci; Valeriana Di Castro; Valentina Caprara; Gabriella Ferrandina; Andrea Sacconi; Giovanni Blandino; Anna Bagnato
Journal:  Oncotarget       Date:  2016-01-26

10.  LOX is a novel mitotic spindle-associated protein essential for mitosis.

Authors:  Myriem Boufraqech; Darmood Wei; Urbain Weyemi; Lisa Zhang; Martha Quezado; Petr Kalab; Electron Kebebew
Journal:  Oncotarget       Date:  2016-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.